Booster doses of the original monovalent COVID-19 vaccine are associated with lower incidence of symptoms in health care personnel 6 weeks postinfection.

Background: The safety and immunogenicity of Viatim, a combined hepatitis A (HA) and typhoid fever (Vi) vaccine, were compared with the monovalent component vaccines up to and 1 month after a ...

In a related JAMA Viewpoint, the authors noted that COVID-19 peaked in 2020 and 2021 as the third highest cause of mortality ...

Regulating drug discovery and pharmaceutical manufacturing, the FDA ensures the safety and effectiveness of innovative ...

Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to ...

The first inactivated influenza vaccine was monovalent (influenza A). In 1942, a bivalent vaccine was produced after the discovery of influenza B. It was later discovered that influenza viruses ...

Today, CDC's Director Rochelle P. Walensky, M.D., M.P.H., signed a decision memo allowing Novavax monovalent COVID-19 boosters for adults.

"While currently approved protein-based RSV vaccines are safe & effective when ... neutralization epitope in Site V compared to AREXVY (monovalent RSV-A), based on an exploratory competitive ...

this is the [monovalent XBB] variant derivative of KOSTAIVE, met all four primary study objectives and key secondary objectives. The study supports co administration of KOSTAIVE with licensed ...

The chair of the national vaccination committee on the latest vaccine developments and the importance for vulnerable groups ...